Recent Patents of Interest in Proteomics
US Patent No. 8,101,367. Antibodies specific to antigens of Bartonella henselae and use of these antigens in immunoassays. Inventors: Tera McCool, Chang Loa, Eli Mordechai, Martin Adelson. Assignee: Medical Diagnostic Laboratories
Covers antibodies to antigenic proteins of Bartonella henselae and the use of these proteins in immunoassays to determine if an individual is or was infected with the organism.
US Patent No. 8,099,242. Systems and methods for characterization of molecules. Inventors: Arnon Chait, Boris Zaslavsky. Assignee: Analiza
Provides systems for the detection, identification, or characterization of the differences between biomolecules and molecules interacting with biomolecules in two or more mixtures. The methods could be used for discovering diagnostic markers and screening for such markers once they have been identified.
US Patent No. 8,097,472. System and method for the separation of analytes. Inventors: Wayne Schneider, James Baraniuk. Assignees: Science Applications International Corporation, Georgetown University
Covers a separations device that uses capillary isolectric focusing to separate an analyte into fractions in a first microchannel and then directs the fractions into a set of second microchannels based on the buffer characteristics in each of the channels.
US Patent No. 8,097,469. Method and system for determining whether a drug will be effective on a patient with a disease. Inventors: Heinrich Roder, Maxim Tsypin, Julia Grigorieva. Assignee: Biodesix
Covers a mass spectrometry-based method of determining whether a patient will respond to a drug by comparing test spectra produced from analysis of a serum sample against a group of class-labeled spectra.
US Patent No. 8,097,468. Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies. Inventors: Maher Albitar, Elihu Estey, Hagop Kantarjian, Francis Giles, Michael Keating. Assignee: Board of Regents, The University of Texas System
Covers the use of a protein signature in plasma to diagnose and predict the clinical behavior of hematologic malignancies such as leukemia by generating protein spectra, comparing these spectra with clinical data, and identifying protein spectra that correlate with the clinical data.
US Patent No. 8,097,463. Use of arylboronic acids in protein labeling. Inventors: Ralf Hoffmann, Helga Hummel, Volker Weiler. Assignee: Koninklijke Philips Electronics
Covers tagging of histidine in polypeptides with arylboronic acid tagging reagents for identifying proteins in a sample.
US Patent No. 8,097,425. Multiplex protein fractionation. Inventors: Michael Urdea, Michael McKenna, Scott Eastman. Assignee: Tethys Bioscience
Covers methods, compositions, and kits for multiplex fractionation of proteins in a sample using protein-binding molecules like small epitope antibodies or aptamers.
US Patent No. 8,084,734. Laser desorption ionization and peptide sequencing on laser induced silicon microcolumn arrays. Inventors: Akos Vertes, Yong Chen. Assignee: The George Washington University
Covers a method of producing a laser-patterned silicon surface for use in laser desorption ionization by subjecting a silicon substrate to multiple laser shots to generate a homogenous microcolumn array.
US Patent No. 8,084,214. Treatment solution, method for pretreatment, method for acquiring information and method for detection. Inventors: Hiroyuki Hashimoto, Manabu Komatsu, Satoru Hatakeyama. Assignee: Canon Kabushiki Kaisha
Covers a method for high sensitivity identification of proteins in cells by: treating tissue slices with an aqueous solution contain gold particles and a digestive enzyme; measuring a 2D distribution of fragmented peptides by TOF-SIMS; and visualizing the 2D distribution of the target protein.
US Patent No. 8,084,034. Proteins. Inventors: Christian Rohlff, Alasdair Stamps. Assignee: Oxford BioTherapeutics
Presents polypeptides that are of use in screening, diagnosis, and prognosis of a variety of cancers, along with affinity reagents that detect or modulate the expression of these polypeptides.